Reply ot the article "Continuously infused carboplatin used as radiosensitizer in locally unresectable no-small-cell lung cancer: a multicenter phase III study", by Groen et al. (Ann Oncol 2004; 15: 427-432).
Jeremic
B
B
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D015999:Multivariate Analysis; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D015203:Reproducibility of Results; D012107:Research Design
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D016190:Carboplatin